Tofacitinib

Catalog No. A17252

Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

Product Citations

Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812

Technical details

Catalog Num	A17252
M. Wt	312.37
Formula	C16H20N6O
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	477600-75-2
Synonyms	Tasocitinib; CP-690550
SMILES	O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1

Biological Activity

Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

Solubility *

In vitro (25°C)	DMSO	Warmed: 56 mg/mL (179.27 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	2% DMSO+30% PEG 300+ddH2O	4 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	32.01 mL	160.07 mL	320.13 mL
0.5 mM	6.4 mL	32.01 mL	64.03 mL
1 mM	3.2 mL	16.01 mL	32.01 mL
5 mM	0.64 mL	3.2 mL	6.4 mL

*The above data is based on the productmolecular weight 312.37. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.